跳至主要内容
临床试验/EUCTR2006-003580-31-NL
EUCTR2006-003580-31-NL进行中(未招募)不适用

A Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

Morphotek0 个研究点目标入组 60 人开始时间: 2007年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Morphotek
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • age over 18 years
  • diagnosis of epithelial platin-sensitive ovarian cancer in first relapse after a remission of 6 - 18 months
  • surgery to remove tumor before first remission
  • CA 125 elevation before first tratment
  • CA 125 elevation at the time of relapse
  • life expectancy over 6 months
  • ECOG performance status 0-2
  • eligible for retreatment with the same chemotherapy regimen that was used to induce remission
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • known central nervous system tumor involvement
  • evidence of other active malignancy requiring treatment
  • Clinically significant heart disease
  • ECG demonstrating clinically significant arrythmias
  • active serious systemic disease
  • active hepatitis or HIV infection
  • Treatment within three months with immunomodulatory therapy
  • breast-feeding, pregnancy or likely to become pregnant during study
  • participation in parallel studies

研究者

发起方
Morphotek

相似试验

A Study of the Efficacy of MORAb-003 in Subjects... | 临床试验